^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Glioblastoma
    Drug:tesevatinib (KD019) (EGFR inhibitor, HER2 inhibitor, VEGFR inhibitor, EphB4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

    Excerpt:
    ...Progression-Free Survival (PFS) at 6 months- EGFRvIIIpos`Progression-Free Survival (PFS) at 6 months - EGFR gene amplified`Overall Survival at 9 months`Overall Survival at 9 months - EGFRvIIIpos`Median Overall Survival at 9 months - EGFR gene amplified`Evaluate the concentration of tesevatinib in patients with and without systemic steroid treatment.`...
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    In vivo efficacy of tesevatinib in patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling

    Published date:
    03/30/2021
    Excerpt:
    Overall, tesevatinib efficacy in EGFR amplified PDX GBM models is robust in vitro but relatively modest in vivo, despite a high brain-to-plasma ratio.
    DOI:
    10.1158/1535-7163.MCT-20-0640